Olfactory receptor family 7 subfamily C member 1 is a novel marker of colon cancer-initiating cells and is a potent target of immunotherapy

Clinical Cancer Research

Volumn 22, Issue 13, 2016, Pages 3298-3309

  Morita, Rena ^a   Hirohashi, Yoshihiko ^a   Torigoe, Toshihiko ^a   Ito Inoda, Satoko ^a   Takahashi, Akari ^a   Mariya, Tasuku ^a   Asanuma, Hiroko ^a   Tamura, Yasuaki ^a   Tsukahara, Tomohide ^a   Kanaseki, Takayuki ^a   Kubo, Terufumi ^a   Kutomi, Goro ^a   Mizuguchi, Toru ^a   Terui, Takeshi ^b   Ishitani, Kunihiko ^b   Hashino, Satoshi ^c   Kondo, Toru ^d   Minagawa, Nozomi ^c   Takahashi, Norihiko ^c   Taketomi, Akinobu ^c   Todo, Satoru ^c   Asaka, Masahiro ^c   Sato, Noriyuki ^a   more..

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Higashi Sapporo Hospital   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OLFACTORY RECEPTOR FAMILY 7 SUBFAMILY C MEMBER 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; SMALL INTERFERING RNA; TUMOR MARKER;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENICITY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE POPULATION CELL; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BIOSYNTHESIS; COLON TUMOR; CYTOTOXIC T LYMPHOCYTE; DRUG SCREENING; GENETICS; HT-29 CELL LINE; IMMUNOLOGY; IMMUNOTHERAPY; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; OLFACTORY RECEPTOR; PATHOLOGY; PROCEDURES; PROGNOSIS; RNA INTERFERENCE; SCID MOUSE; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANIMALS; BIOMARKERS, TUMOR; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, ODORANT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPHEROIDS, CELLULAR; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84977103239     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1709     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how?Br J Cancer 2009;100:1704-19.
3. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-60.
4. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Re 2006;66:9339-44.
5. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
6. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy?J Patholo 2011;223:147-61.
7. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-7.
8. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-7.
9. Hirohashi Y, Torigoe T, Inoda S, Kobayasi J, Nakatsugawa M, Mori T, et al. The functioning antigens: beyond just as the immunological targets. Cancer Sci 2009;100:798-806.
10. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012;1:1557-76.
11. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
12. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, Ly DP, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010;466:133-7.
13. Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N. Immune Responses to Human Cancer Stem-like Cells/Cancer-initiating Cells. Cancer Sci 2016;107:12-7.
14. Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, et al. Cytotoxic T lymphocytes efficiently recognize human colon cancer stemlike cells. Am J Pathol 2011;178:1805-13.
15. Kano M, Tsukahara T, Emori M, Murase M, Torigoe T, Kawaguchi S, et al. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci 2011;102:1443-7.
16. Nakatsugawa M, Hirohashi Y, Torigoe T, Inoda S, Kiriyama K, Tamura Y, et al. Comparison of speedy PCR-ssp method and serological typing of hlaa24 for Japanese cancer patients. J Immunoassay Immunochem 2011;32:93-102.
17. Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012;72:2844-54.
18. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 2011;91:1796-804.
19. Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
20. Yamada R, Takahashi A, Torigoe T, Morita R, Tamura Y, Tsukahara T, et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013;81:428-34.
21. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002;8:1731-9.
22. Inoda S, Hirohashi Y, Torigoe T, Nakatsugawa M, Kiriyama K, Nakazawa E, et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009;32:474-85.
23. Morita R, Hirohashi Y, Nakatsugawa M, Kanaseki T, Torigoe T, Sato N. Production of multiple CTL epitopes from multiple tumor-associated antigens. Methods Mol Biol 2014;1139:345-55.
24. Goossens-Beumer IJ, Zeestraten EC, Benard A, Christen T, Reimers MS, Keijzer R, et al. Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. Br J Cancer 2014;110:2935-44.
25. Hirohashi Y, Torigoe T, Inoda S, Morita R, Kochin V, Sato N. Cytotoxic T lymphocytes: Sniping cancer stem cells. Oncoimmunology 2012;1:123-5.
26. Gimelbrant AA, Stoss TD, Landers TM, McClintock TS. Truncation releases olfactory receptors from the endoplasmic reticulum of heterologous cells. J Neurochem 1999;72:2301-11.
27. Durzynski L, Gaudin JC, Myga M, Szydlowski J, Gozdzicka-Jozefiak A, Haertle T. Olfactory-like receptor cDNAs are present in human lingual cDNA libraries. Biochem Biophys Res Commun 2005;333:264-72.
28. Kang N, Koo J. Olfactory receptors in non-chemosensory tissues. BMB Rep 2012;45:612-22.
29. Neuhaus EM, Zhang W, Gelis L, Deng Y, Noldus J, Hatt H. Activation of an olfactory receptor inhibits proliferation of prostate cancer cells. J Biol Chem 2009;284:16218-25.
30. Cui T, Tsolakis AV, Li SC, Cunningham JL, Lind T, Oberg K, et al. Olfactory receptor 51E1 protein as a potential novel tissue biomarker for small intestine neuroendocrine carcinomas. Eur J Endocrinol 2013;168:253-61.
31. Wei P, Tang H, Li D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. PLoS One 2012;7:e46887.
32. Spehr M, Gisselmann G, Poplawski A, Riffell JA, Wetzel CH, Zimmer RK, et al. Identification of a testicular odorant receptor mediating human sperm chemotaxis. Science 2003;299:2054-8.
33. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507.
34. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.
35. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009;27:40-8.
36. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol 2010;34:1193-8.
37. Du L, Yang Y, Xiao X, Wang C, Zhang X, Wang L, et al. Sox2 nuclear expression is closely associated with poor prognosis in patients with histologically node-negative oral tongue squamous cell carcinoma. Oral Oncol 2011;47:709-13.
38. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, et al. Prognostic impact of the expression of ALDH1 and SOX2 in urothelial cancer of the upper urinary tract. Modern Pathol 2013;26:117-24.
39. Schrock A, Goke F, Wagner P, Bode M, Franzen A, Braun M, et al. Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer. PLoS One 2013;8:e59201.
40. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells. Cancer Res 2008;68:6281-91.
41. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70:10433-44.
42. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene 2010;29:2153-9.
43. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Cancer Res 2011;71:4260-8.
44. Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, et al. In situ validation of an intestinal stem cell signature in colorectal cancer. Gut 2013;62:1012-23.
45. Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, et al. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol 2012;41:1643-52.
46. Mori T, Nishizawa S, Hirohashi Y, Torigoe T, Tamura Y, Takahashi A, et al. Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population. Exp Mol Pathol 2012;92:27-32.
47. Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012;72:1853-64.